What types of alopecia or hair loss conditions might TDM-105795 be designed to target based on current research?

What is known about TDM-105795

TDM-105795 is an experimental topical drug developed by Technoderma Medicines. The developer and a 2025 review describe it as a thyroid-receptor β1 agonist, a compound that mimics some effects of thyroid hormone. It is not approved anywhere.

It has been tested only in men with androgenetic alopecia (male-pattern hair loss). The trial registry lists three studies:

• a Phase 1 safety study in 30 men (NCT04913519, completed 2021);
• a Phase 1 study in 32 men (NCT05244980, completed 2023);
• a 16-week Phase 2 trial in 71 men with mild to moderate androgenetic alopecia, comparing 0.0025%, 0.02% and a vehicle (inactive) solution (NCT05802173).

Results for the Phase 2 trial were posted on ClinicalTrials.gov in November 2025. The mean change in non-vellus hair count at 16 weeks was +20.3 (0.0025%), +22.4 (0.02%) and +14.0 (vehicle) hairs per cm², with wide spread between participants. No statistical comparison has been posted, and the results have not been published in a peer-reviewed journal. The registry reports no serious adverse events over 16 weeks.

Which conditions it is being studied for

There is no research on TDM-105795 in any condition other than male androgenetic alopecia. It has not been studied in women, in alopecia areata, in telogen effluvium or in scarring alopecias. Any suggestion that it could help those conditions is speculation, not a finding.

Why androgenetic alopecia

Androgenetic alopecia is the most common form of hair loss. The follicles shrink over time under the influence of dihydrotestosterone but are not destroyed, which is why drugs aimed at restarting or prolonging hair growth are usually tested there first. Thyroid hormone is known to affect human hair follicles in laboratory studies, which is the rationale the developer gives for this compound.

What is still unknown

• Whether the difference from vehicle is statistically significant or large enough to matter.
• How it compares with minoxidil or finasteride; no head-to-head trial exists.
• Long-term safety. No thyroid-function results have been published.
• Whether it works in women or in other types of hair loss.

Until peer-reviewed results are published, TDM-105795 remains an investigational compound.

References

ClinicalTrials.gov. NCT05802173: A randomized, double-blind, vehicle-controlled, parallel group, multi-dose study to evaluate the efficacy and safety of TDM-105795 in male subjects with androgenetic alopecia. https://clinicaltrials.gov/study/NCT05802173

ClinicalTrials.gov. NCT04913519: A Phase 1 study of TDM-105795 topical solution in male subjects with androgenetic alopecia (AGA). https://clinicaltrials.gov/study/NCT04913519

ClinicalTrials.gov. NCT05244980: A study of TDM-105795 in male subjects with androgenetic alopecia (AGA). https://clinicaltrials.gov/study/NCT05244980

Kim, J., Song, S. Y., & Sung, J. H. (2025). Recent advances in drug development for hair loss. International Journal of Molecular Sciences, 26(8), 3461. https://doi.org/10.3390/ijms26083461

van Beek, N., Bodó, E., Kromminga, A., et al. (2008). Thyroid hormones directly alter human hair follicle functions: anagen prolongation and stimulation of both hair matrix keratinocyte proliferation and hair pigmentation. Journal of Clinical Endocrinology & Metabolism, 93(11), 4381–4388. https://pubmed.ncbi.nlm.nih.gov/18728176/